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Abstract To reduce the duration of neutropenia after
conditioning chemotherapy and autologous peripheral blood
stem cell transplantation (APBSCT), granulocyte-colony
stimulating factors (G-CSF) are commonly administered.
We retrospectively evaluated the impact of pegfilgrastim
compared to filgrastim on neutrophil engraftment, hospital
stay, and supportive measures in patients with multiple
myeloma after conditioning with Melphalan 200 (Mel200)
followed by APBSCT. Ninety-two APBSCT after Mel200
treatment were performed in 72 patients between January
2006 and December 2009 at our institution. Patients received
either single-dose pegfilgrastim (n=46; 50%), or daily
filgrastim (n=46; 50%) after APBSCT (median duration of
filgrastim use, 9 days; range, 3–14 days). Duration of
neutropenia grade IV was shorter with pegfilgrastim com-
pared with filgrastim (median, 5 days (range, 3–14 days)
versus 6 days (range, 3–9 days), p=0.0079). The length of
hospitalization differed significantly (pegfilgrastim (median,
14.5 days; range, 11–47 days) versus filgrastim (median,
15.5 days; range, 12–64 days), p=0.024). Pegfilgrastim-
treated patients had less red blood cell transfusions (median,
0 transfusions (range, 0–10) versus 0.5 transfusions (range,
0–9), p=0.00065). Pegfilgrastim was associated with reduced
cost of the treatment procedure compared with filgrastim (p=
0.031). Pegfilgrastim appears to be at least equivalent to
filgrastim without additional expenditure in myeloma
patients treated with Mel200 and APBSCT.
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Abbreviations
MM multiple myeloma
APBSCT autologous peripheral blood stem cell
transplantation
G-CSF granulocyte-colony stimulating factor
Mel200 high-dose melphalan (200 mg/m2)
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Introduction
Autologous peripheral blood stem cell transplantation
(APBSCT) is an established treatment modality for patients
with multiple myeloma (MM) [1, 2]. Infectious complica-
tions may occur during a period of severe neutropenia that
put the patients at risk for morbidity and mortality after high-
dose chemotherapy [3–5]. To reduce the time to neutrophil
engraftment and eventually the risk for neutropenic fever,
many transplantation centers use granulocyte-colony stimu-
lating factors (G-CSF) after APBSCT, although data on their
impact on relevant clinical parameters as duration and onset
of fever, length of hospital stay, the use of antibiotics,
infectious mortality, and ultimately treatment cost are still
ambiguous [6–9]. This is also reflected by the differing
recommendations of American and European guidelines. The
former recommend the use of G-CSF after APBSCT, while
the latter classify their use as controversial for this indication
[10, 11].
Filgrastim (Neupogen©, Amgen) is the G-CSF most
commonly used in this setting. Due to its short half-life, daily
injections are necessary until neutrophil recovery has been
documented for at least three consecutive days. In the past, our
center had reported on the superiority of filgrastim treatment
after autologous bone marrow transplantation compared with
no administration of filgrastim with respect to neutrophil
recovery and duration of neutropenic fever [12].
Pegfilgrastim (Neulasta©, Amgen) is the pegylated form
of filgrastim. Due to the long-term formulation it has the
advantage over filgrastim of a single application after the
ablative chemotherapy, thus improving patient comfort.
The efficacy of pegfilgrastim has already been shown in
patients treated with conventional doses of chemotherapy
by reducing the duration of neutropenia and the need for
antibiotic treatment [13–15]. Until now, only a few studies
with small or heterogenous patient collectives have been
performed which assess the impact of pegfilgrastim in this
setting [16–20]. The most relevant limitation of the data
available in the literature is that patients with different
diseases treated with different conditioning regimens were
analyzed together, without taking into account that patient
collectives likely differ in terms of chemotherapy associated
toxicity and the necessary patient care [21–23].
Here, we report on the efficacy of pegfilgrastim compared
with filgrastim in patients with multiple myeloma receiving
Melphalan 200 (Mel200) and APBSCT, with special empha-
sis on treatment cost during the post-transplant period.
Patients and methods
We performed a ‘per transplant’ analysis of myeloma
patients receiving high-dose chemotherapy with Mel200
and subsequent APBSCT during the last 4 years (2006–
2009) at our center. The analysis was approved by our local
ethical committee.
Patients received either pegfilgrastim or daily filgrastim after
APBSCT. From January 2006 to December 2007 patients
routinely received filgrastim. Expecting benefits regarding
patient comfort and safety, we decided by late 2007 to
implement a practice change, accordingly from January 2008
to December 2009 pegfilgrastim was generally administered
after APBSCT. No other practice changes within the trans-
plantation program were applied during the whole analysis
period. Pegfilgrastimwas administered as a single fixed dose of
6 mg subcutaneously at day +1 after stem cell reinfusion.
Filgrastim was given at a dose of 5 μg/kg body weight
subcutaneously once daily, starting at day +5 after stem
cell reinfusion, until the absolute neutrophil count (ANC) was
 0:5 109 cells/L for at least three consecutive days. This
analysis includes all patients with multiple myeloma who
received Mel200 during this period. Patients treated with
APBSCT for other diseases or myeloma patients who
received a reduced conditioning chemotherapy (i.e., Mel140)
were excluded from this analysis.
The medical records of the patients and our prospectively
collected transplantation database were screened for hospital
stay, appearance and duration of neutropenic fever, the use of
intravenous antibiotics, and the need for red blood cell and
platelet transfusions during hospital stay, and then compared
between the groups.
Neutropenia was defined as ANC below 0.5 x 109 cells/L.
Fever was defined as body temperature ≥38.4°C. Every day
of fever was considered for analysis when a body temperature
over this cut-off was documented in the patient charts.
Hospitalization time in this analysis was defined as time from
the day of stem cell reinfusion (day 0) to the day of patient's
discharge.
Statistical analyses
Statistical methods comparisons of patient characteristics
were made using either a Mann–Whitney U test, or a
Fisher's exact test, as appropriate. Continuous clinical
outcomes are presented as median (range), and compared
using the Mann–Whitney U test, while binary clinical
outcomes are presented as a percentage, and compared
using Fisher's exact test. Cost analysis is based on the
average cost of blood products, average length of stay, and
on average cost of filgrastim or pegfilgrastim per patient
(compared with the Kruskal–Wallis test).
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All analyses were performed in the R programming
language [24].
Results
Patient demographics
Between January 2006 and December 2009, a total of 122
APBSCTwith subsequent G-CSF support were performed in
MM patients at our institution. Ninety-two (75%) APBSCT
were performed withMel200 in 72 patients and were included
into this analysis. During this time period, 67 (73%) were first
APBSCT, and 25 (27%) were second APBSCT. There was an
equal balance between patients receiving either single-dose
pegfilgrastim or filgrastim after APBSCTwith 46 (50%) cases
per treatment group. Filgrastim was applied after APBSCT for
a median of 9 days (range, 3–14 days). The patient character-
istics were well-balanced between the two groups including
the dose of CD34+ stem cells reinfused and the number of
APBSCT performed (Table 1).
Efficacy
Neutrophil engraftment was faster with pegfilgrastim than
with filgrastim (median 9 days (range, 8–18 days) versus
10 days (range, 8–12 days), p=0.032), and accordingly, the
median duration of neutropenia grade 4 was significantly
shorter in the former patients (median 5 days (range, 3–
14 days) versus 6 days (range, 3–9 days), p=0.0079). No
difference between the two groups was observed regarding
the duration of thrombocytopenia grade 4 (median, 3.5 days
(range, 0–15 days) versus 3 days (range, 0–10 days); p=
0.39). In addition, less red blood cell transfusions were
necessary in the pegfilgrastim-treated patients (median, 0
transfusions (range, 0–10 days) versus 0.5 transfusions
(range, 0–9 days); p=00065). No significant differences
were observed regarding the number of platelet transfusions,
the duration of fever, and the duration of intravenous
antibiotic treatment between the two groups (Table 2).
Overall, 23 (50%) patients receiving filgrastim needed
red blood cell transfusions during their hospital stay
compared with eight (17.4%) pegfilgrastim-treated patients
(p=0.0018). No significant difference was seen in the
number of patients needing intravenous antibiotics or
platelet transfusions. Also, no differences were seen
regarding the incidence of fever or the need for transfer to
the intensive care unit between the two groups (Table 3).
Overall, treatment related mortality was 0%.
Cost analysis
Cost analysis was performed using the Swiss drug prices listed
for the year 2008. The median cost per patient for filgrastim
was 1,979 Swiss francs, compared with 2,077 Swiss francs for
pegfilgrastim (p=0.25, Mann–Whitney U test).
An integrated cost analysis including the cost of the G-CSF
used, the infused blood products, and the hospital stay
Parameter Filgrastim (n=46) Pegfilgrastim (n=46) p value
Age
Median, years 56.5 57.9
Range, years 44–68.7 38–67.7 0.82
Gender
Male, no. (%) 22 (52) 32 (70)
Female, no. (%) 24 (48) 14 (30) 0.056
CD34+ cells reinfused
Median 3.2 3.2
Range 2.0–7.9 2.0–13.0 0.51
Number of APBSCT
First APBSCT, no. (%) 31 (67) 36 (78)
Second APBSCT, no. (%) 15 (33) 10 (22) 0.35
Myeloma type
IgG, no. (%) 28 (61) 27 (59)
IgA, no. (%) 7 (15) 9 (19.5)
IgD, no. (%) 1 (2) 0 (0)
Bence Jones, no. (%) 8 (17) 9 (19.5)
Nonsecretory, no. (%) 2 (4) 1 (2) 0.93
Table 1 Patient characteristics
(‘per transplant’ analysis).
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revealed that treatment cost were lower with pegfilgrastim
than with filgrastim (p=0.031, Mann–Whitney U test) with
an additional expenditure of 1,274 Swiss francs per patient
(6%) in the filgrastim-treated cohort.
Discussion
Our objective was to assess the impact of pegfilgrastim on
the clinical outcome of patients with multiple myeloma
who received melphalan in a dose of 200 mg/m2, since
patients with different diseases may differ in terms of
demographics, and conditioning regimens may also vary in
terms of toxicity [21–23].
In this homogenous patient collective, we observed that
pegfilgrastim is able to reduce the duration of grade 4
neutropenia and, accordingly, the time to engraftment when
compared with filgrastim.
Furthermore, the length of hospital stay was reduced
with pegfilgrastim. This finding may be directly associ-
ated with the reduced time to engraftment since our
patients are generally discharged when neutrophil
recovery has been documented and no additional
reasons for inpatient treatment are present. Interestingly,
we could not observe a reduction in the incidence of
fever and the need for intravenous antibiotics during the
hospitalization. Although fever was documented in the
majority of patients in both subgroups (72% and 63%,
Parameter Filgrastim (n=46) Pegfilgrastim (n=46) p value
Length of hospital stay
Median, days 15.5 14.5
Range, days 12–64 11–47 0.024
Time to Engraftment
Median, days 10 9
Range, days 8–12 8–18 0.032
Duration of neutropenia grade 4
Median, days 6 5
Range, days 3–9 3–14 0.0079
Duration of thrombocytopenia grade 4
Median, days 3 3.5
Range, days 0–10 0–15 0.39
Duration of fever
Median, days 2 1
Range, days 0–12 0–19 0.13
Duration of i.v. antibiotic treatment
Median, days 6 5.5
Range, days 0–22 0–36 0.12
Red blood cell transfusions
Median, number 0.5 0
Range, number 0–9 0–10 0.00065
Platelet transfusions
Median, number 1 1
Range, number 0–8 0–10 0.92
Table 2 Clinical outcomes in
MM patients treated with
Mel200
Data presented as median
(range)
p values from Mann–Whitney
U test
i.v. intravenous
Parameter Filgrastim (n=46) Pegfilgrastim (n=46) p value
Intravenous antibiotics, no. (%) 41 (89) 37 (80) 0.38
Incidence of fever, no. (%) 33 (72) 29 (63) 0.51
Red blood cell transfusions, no. (%) 23 (50) 8 (74) 0.0018
Platelet transfusions, no. (%) 36 (78) 34 (74) 0.81
Transfer to ICU, no. (%) 3 (7) 2 (4) 1
Table 3 Clinical outcomes
(binary) in MM patients treated
with Mel200
Data presented in absolute
patient numbers and percent
p values from Fisher's exact test
ICU intensive care unit
92 Ann Hematol (2011) 90:89–94
respectively), the duration of fever was similar and generally
short lasting in both groups (median of 2 days with filgrastim
and 1 day with pegfilgrastim, respectively), which may also
explain the lack of a significant difference in the use of
intravenous antibiotics.
Filgrastim was administered for a median of 9 days
per case, and therefore absolute treatment cost of the two
G-CSF did not differ significantly between the two
groups. In contrast, an integrated analysis including the
cost of G-CSF applied, the cost of blood products, and
the daily cost of inpatient care at our clinic revealed that
treatment with pegfilgrastim reduced the overall cost by
6% compared to filgrastim. The main reasons for this
finding are probably the faster discharge of patients who
received pegfilgrastim and the reduced need for blood
products.
The latter observation is of particular interest as it is
known that post-transplant use of G-CSF may impair the
recovery of other hematopoietic progenitors. Bensinger and
colleagues have suggested a steal phenomenon whereas
myeloid progenitors may be favored over platelet progen-
itors by the use of G-CSF resulting in delayed platelet
recovery [25]. Further evidence for such a mechanism
comes from the use of G-CSF in congenital neutropenia
where overstimulation of the neutrophilic compartment
with pegfilgrastim has been reported to result in a
thrombocytopenia among other adverse effects [26]. In
our series, no delay in erythrocyte or thrombocyte recovery
was observed with the fixed dose of pegfilgrastim, and the
supposed better control of the hematopoiesis by using
filgrastim appears not to be superior with regard to blood
transfusions. The non-inferiority of pegfilgrastim with
regard to this critical issue is therefore another important
finding of this analysis.
A few non-randomized retrospective analyses and small
prospective studies have reported on this issue, but to our
knowledge, this is the largest homogenous patient cohort
analyzed so far to address this question [16–20]. Strength of
this analysis is that patient care within our autologous
transplantation program is highly regularized by standard-
ized operating procedures and relevant clinical patient
data is collected prospectively within our transplantation
database.
Further, by focussing on one entity and one standardized
conditioning regimen any possible bias caused by the
heterogeneity of patients and treatment modalities is
minimized.
In conclusion, considering the nature of this analysis—
retrospective, single-center design, superiority of pegfil-
grastim in this setting cannot be claimed, but equivalence of
the two G-CSF formulations is highly probable.
Pegfilgrastim appears to be at least comparable to
filgrastim regarding the time to neutrophil engraftment, the
length of hospital stay, the need for red blood cell transfusions
and the treatment cost in MM patients undergoing condition-
ing with Mel200 followed by APBSCT. No differences
between the two G-CSF administered regarding incidence
and duration of neutropenic fever, use of intravenous anti-
biotics, and need for platelet transfusions were detectable. For
confirmation of these data, a randomized prospective trial
with a sufficient and homogenous patient collective would be
preferable. However, in the absence of definitive proof we
provide clinicians with promising data regarding safety and
equivalence of the application of pegylated G-CSF in
autologous transplantation following Mel200 as conditioning
regimen.
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